Clinical Trials Directory

Trials / Unknown

UnknownNCT06238089

Anti-psychotic Drug Prescribing Patterns Within Specialist Adult ID Services in England and Wales

A Novel Way to Understand and Communicate the Burden of Antipsychotic Prescribing for Adults Across Specialist Intellectual Disability Services in England and Wales.

Status
Unknown
Phase
Study type
Observational
Enrollment
600 (estimated)
Sponsor
University of Plymouth · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The overall aim of this observational study is to establish the anti-psychotic prescribing patterns across specialist intellectual disability (ID) services in England and Wales by collecting cross-sectional retrospective data at 7 annual time-points (1st July) from 2017 to 2023.

Detailed description

Feasibility protocol objectives: 1. Is it feasible to identify People with Intellectual Disabilities (PwID) who have been prescribed 2 or more anti-psychotic medications over 7 years retrospectively. 2. It is possible to obtain a complete data set for each patient identified and therefore be able to explore the prescribing patterns across the eight sites. 3. Is it feasible to quantify anti-psychotic treatment (APT) prescribing in PwID as chlorpromazine equivalent dose values across different healthcare Trusts in England and Wales. Main objectives: 4. To explore yearly and overall prescribing patterns among PwID (with or without mental-health reasons (psychiatric co-morbidities)) in receipt of ≥2 forms of anti-psychotic treatment (multiple) over time? 5. How has multiple anti-psychotic treatment prescribing changed between 2017 and 2023 using chlorpromazine equivalent dose values, in PwID with mental health and no mental health indications? 6. What has been the impact of the COVID-19 pandemic (and corresponding lockdown restrictions in England and Wales) on multiple anti-psychotic treatment prescribing among PwID? 7. Can the NHS England Statistical Process Control tool (SPC) be utilised to track yearly anti-psychotic treatment prescribing among PwID receiving multiple forms of anti-psychotic treatment, and monitor variation between services (sites) and patient groups (e.g. psychiatric co-morbidities; challenging behaviour).

Conditions

Timeline

Start date
2023-12-19
Primary completion
2024-04-01
Completion
2024-04-01
First posted
2024-02-02
Last updated
2024-02-02

Locations

8 sites across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT06238089. Inclusion in this directory is not an endorsement.